Navigation Links
Study shows universal surveillance for MRSA significantly decreased HAIs at PCMH

Greenville, NC (July 13, 2010) Pitt County Memorial Hospital (PCMH) today announced results of a study demonstrating that universal surveillance for methicillin-resistant Staphylococcus aureus (MRSA) decreased health care-associated infections (HAIs) related to devices. Infection rates decreased 68 percent for ventilator-associated pneumonias (VAP); 51 percent for central line-associated bacteremias (CLA-BSI); and 49 percent for catheter-associated urinary tract infections (CAUTI).

The study was led by Keith Ramsey, M.D., medical director for infection control at PCMH, and professor of medicine at The Brody School of Medicine at East Carolina University. Universal surveillance, also known as all-admissions surveillance, introduces the testing of all patients upon admission, not just high-risk patients, and has been shown to be far more effective than targeted active surveillance when monitoring for MRSA infections. If patients test positive for MRSA, they are put on contact precautions that include isolation, hand hygiene, room signage, patient-dedicated equipment, personal gowns and gloves, and they are decolonized with mupirocin/chlorhexidine bath.

"At PCMH we have made it our mission to take pre-emptive action to reduce the risk of patients transmitting or acquiring an infection while under our care," Ramsey said. "This particular study demonstrates that universal surveillance plus eradication help to reduce HAIs related to devices, which continues to be a major challenge for hospitals and health care facilities in the United States."

The study was presented today by Kathy Cochran, manager of infection control at PCMH, during a poster session (Poster #: 8-056) at the Association for Professionals in Infection Control and Epidemiology (APIC) 2010 annual conference in New Orleans. The BD GeneOhm MRSA assay, an in vitro molecular diagnostic test that provides definitive results within two hours of laboratory time, was used in the study.

During the surveillance period, rates for MRSA-associated HAIs decreased for each device as follows:

  • VAPs per 1,000 vent days decreased 68 percent from 1.065-to-0.296 (p < 0.006) in the intervention year, and to 0.183 (p < 0.002) in the maintenance year.
  • CLA-BSIs per 1,000 line days decreased 51 percent from 0.244-to-0.124 (p < 0.292) in the intervention year, and to 0.111 in the maintenance year (p < 0.196).
  • CAUTI rates per 1,000 foley days decreased 49 percent from 0.207-to-0.101 (p< 0.254) in the intervention year, and to 0.099 (p < 0.266) during the maintenance year.

In addition to the poster presentation, Ramsey will present Universal MRSA Screening: Selecting the Best Practice for the Best Price on Wednesday, July 14, 2010 at 4 p.m. in Conference Auditorium 3. In addition, Ramsey will discuss necessary steps for implementing universal admission screening for MRSA.

According to the Centers for Disease Control and Prevention (CDC) in American hospitals alone, HAIs account for an estimated 1.7 million infections and 99,000 associated deaths each year. Of these infections:

  • 32 percent of all HAIs are urinary tract infections
  • 22 percent are surgical site infections
  • 15 percent are pneumonia (lung infections)
  • 14 percent are bloodstream infections.

MRSA bacteria can cause a potentially fatal infection that does not respond to commonly used antibiotics and is a significant cause of HAIs. The CDC estimates that approximately 126,000 people are hospitalized each year with MRSA infections, and about 19,000 die, with an estimated annual cost of $3.2 billion to $4.2 billion to U.S. hospitals.


Contact: Kathy Vigneault
Manning Selvage & Lee

Related medicine news :

1. Study finds lifelong doubling in death risk for men who are obese at age 20 years
2. Arsenic shows promise as cancer treatment, Stanford study finds
3. Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma
4. Mayo Clinic study finds apathy and depression predict progression from mild cognitive impairment
5. New study suggests tart cherry juice can be a natural solution for insomnia
6. Study implicates new epigenetic player in mental retardation and facial birth defects
7. LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds
8. New UC Davis study finds early Alzheimers identification method
9. Rat Study Sheds Light on Cocaine Addiction
10. Study: Medicare policy may account for growing length of hospice stays in nursing homes
11. Study Suggests Link Between HPV, Skin Cancer
Post Your Comments:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: